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 INTRODUCTION 
 
 
“Diabetes Mellitus is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action or both”. 
 
The effect of Diabetes Mellitus includes long term damage, 
dysfunction and failure of various organs especially eyes, kidney, heart and 
blood vessels. Chronic complications are responsible for high morbidity and 
mortality and cause disproportionately high number of hospital days. 
 
In 1921, Banting, Best and Macleod demonstrated pancreatic 
extracts lower blood sugars. In 1936, Antanio discovered oral hypoglycemic 
agents. W. R. Jordan described association of diabetes with foot lesions.1 
The incidence of diabetes and its complications are on a rise, the risk 
of lower extremity amputations is 15 fold higher in diabetics as compared to 
non-diabetics.2 
 
Essential to mention here that chronic diabetic foot ulcer is the leading 
cause of amputations in these patients, The incidence of diabetes and its 
complications are on a rise, the risk of lower extremity amputations is 15 
fold higher in diabetics as compared to non-diabetics.2 Essential to mention 
2 
 
here that chronic diabetic foot ulcer is the leading cause of amputations in 
these patients, also that 15% of all diabetics develop diabetic ulcer and the 
most commonest site being the foot also that 15% of all diabetics develop 
diabetic ulcer and the most commonest site being the foot. Although the 
fundamental pathophysiologic factors leading to diabetic ulcer remain 
incompletely understood, the triad of neuropathy, ischemia and infections 
commonly is considered the most important. 
 
These diabetic ulcers are known to be resistant to conventional 
treatment and may herald severe complications if not treated wisely.3,4,5 
 
The wound environment contains a variety of growth factors .Platelet 
rich plasma release. Platelet- derived growth factor is of particular relevance 
due to its chemotactic, mitogenic, angiogenic, and stimulatory effects 
leading to matrix formation and wound bed granulation. PDGF may be of 
significant benefit of diabetics as recalcitrant diabetic wounds have been 
found to be deficient in or absent of PDGF.6 Platelet-derived growth factor 
(PDGF) is one of the numerous  growth factors, or  proteins that regulate  
cell growth and  division. In particular, it plays a significant role in  blood 
vessel formation (angiogenesis). 
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PRP is an effective concentration of multiple growth factors by virtue 
of platelets alone, which contain plasma proteins ,namely fibrin , fibronectin 
and vitronectct .This  cocktail of GFs is pivotal in diabetic foot for 
modulation of tissue repair and regeneration.plasma proteins as a scaffold  
for connective tissue and epithelial migration. 
  
PrepackagedGFs degranulation occurs in platelets occur upon 
“activation” on coming in contact with coagulation triggers.GFs secreted in 
turn bind to their respective transmembrane receptors expressed over adult 
mesenchymal stem  cells, fibroblasts epidermal  cells,endothelial cells.     
 
The efficacy of certain growth factors in healing various injuries and 
the concentrations of these growth factors found within PRP are the 
theoretical basis for the use of PRP in tissue repair. 
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Platelet rich plasma contain following growth factors:  
 platelet-derived growth factor 
 transforming growth factor beta 
 fibroblast growth factor 
 insulin-like growth factor 1 
 insulin-like growth factor 2 
 vascular endothelial growth factor 
 epidermal growth factor 
 Interleukin 8 
 keratinocyte growth factor 
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AIM AND OBJECTIVE OF THE STUDY 
 
 
To compare the efficacy of Platelet rich plasma (PRP) dressing Vs 
conventional wound dressing in wound reduction in patients with chronic 
diabetic foot ulcers, admitted in Stanley  medical college , Chennai. 
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REVIEW OF LITERATURE 
 
 
Foot ulceration, sepsis and amputation are known and feared by 
almost every person who has diabetes diagnosed. Yet these are potentially 
the most preventable of all diabetics14. Life time risk for foot ulcers with 
diabetes is 15%4. Important factor to determine outcome of diabetic foot is 
severity and not ulcer site15. 
 
The incidence of diabetes and complications are on rise. In well-
studied town of Framingham the prevalence of diabetes has risen from 0.9% 
in 1958 to 3% in 1993. India has dubious distinction of highest number of 
diabetics in the world. In the year 1995 there were 19.4 million diabetics 
which is expected to rise to 57.2 million by 2025.5 
 
Diabetic foot being one of the most common complications, where 
15% of all diabetics develop diabetic ulcers, the most common site being the 
foot. Every 2% rise in glycosylated hemoglobin increases the risk of lower 
extremity ulcers by 1.6 times and lower extremity amputation by 1.5 times16. 
 
Diabetes has highest risk factor associated with limb threatening 
ischaemia. Trivial trauma secondary to neuropathy and distorted pedal 
architecture causes ulcerations. 15% of all diabetics develop foot ulcer. 20% 
of admissions in diabetics are for foot problems.4 
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HISTORICAL BACKGROUND OF WOUND HEALING 
 
 The treatment and healing of wounds are some of the oldest subjects 
discussed in the medical literature and probably earliest problems of 
human race.17  
 Early surgeons like Ambrose, Pare, John Hunter, & Sir James Paget 
have given some scientific knowledge to their handling of wounds, 
particularly those resulted from war.18  
 Halsted was intensely interested in wound healing process.  
 In the early 1900’s Carrel & his associates made investigations with 
the scientific approach to wound healing. Later Carrel (1916), Harvey 
& Howe’s (1930), studied incised wounds & contributed to the 
knowledge of wound healing.18  
 There is a saying; “If there were no regeneration, there would be no 
life; if everything regenerated, then, there would be no death”.  
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HEALING, REGENERATION & REPAIR 
 
Healing 
 
“Body replacement of destroyed tissues by the living tissue” or 
“Integrated series of cellular & biochemical events which restores the 
functional integrity & regains the strength of injured tissue”. 
 
Regeneration 
 
“It is a process of replacement of lost tissue by an identical type of 
fresh tissue”. There is proliferation of surrounding undamaged specialized 
cells.18 Seen in- [1] Epidermis [2] Endothelium [3] Liver cells [4] Mucous 
membrane. 
 
Repair 
 
It is the replacement of lost tissues by granulation tissue, which 
matures to form the scar tissue”. This is inevitable, when the surrounding 
specialized cells do not possess the capacity to proliferate e.g. muscle & 
nervous tissue. 
Repair begins during the early phases of inflammation but reaches 
completion usually after the injurious influence has been neutralised.31 
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During repair, the injured tissue is replaced by.19 
 
• Regeneration of native parenchyma cells  
 
 
• By filling of the defect with fibroblastic tissue (scarring).  
 
 
• By a combination of these two processes.  
 
HEALING: 
 
Definition: 
 
“Body replacement of destroyed tissues by the living tissue” or 
“Integrated series of cellular & biochemical events which restores the 
functional integrity & regains the strength of injured tissue” 
Phases of Healing: 
Wound healing & repair are complex processes that involves dynamic 
series of events. 
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[1] Coagulation  
[2] Inflammation  
[3] Fibroplasia, Angiogenesis, Proliferation & Granulation tissue 
formation.  
[4] Epithelization  
[5] Collagen Synthesis  
[6] Wound contraction / Tissue Remodeling / Scar Maturation  
 
COAGULATION : 
 
• Helps in preventing blood loss, covering wound surface, & holding 
the wound edges together & thus contributing to the healing process.  
 
• Knighton et al (1982) & Ross (1980) have shown equivocally that 
fibrin & platelets play an important role in initiating the wound 
healing.  
11 
 
  
 
 
 
 
Fig. 2.1 : Mechanism of Coagulation 
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GRANULATION PHASE OF WOUND HEALING : 
 
• Phases of wound healing coming under this phase are : 
Fibroplasia, Angiogenesis, Proliferation  
 
What is Granulation tissue19 
 
‘This is a highly vascular tissue, containing largely of 
 
1. Fibroblasts [Proliferating fibroblasts + Products of Fibroblasts]  
 
2. Endothelial cells lining capillaries of newly sprouting blood vessels  
 
3. Macrophages  
 
4. Pleuripotent Pericytes  
 
Above all are embedded in a matrix consisting 
 
1. Fibronectin  
 
2. Proteoglycans rich in Hyaluronicacid & collagen [This collagen is at 
first mainly of Type-III, changing later to Type I]  
 
Why named as ‘Granulation Tissue’? 
 
The term granulation tissue derived from it’s pink, soft, granular 
appearance on  the surface of wounds.19 
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FUNCTIONS OF GRANULATION TISSUE :- 
 
 
• Fill the gap of the wound  
 
• Supports the growing & migrating epithelial cells –The connective 
tissue matrix of granulation tissue forms nutritive substrate, over 
which regenerating epidermis can migrate & is gradually replaced 
by scar tissue  
Factors which play important role in Granulation tissue formation: 
 
• Chemotactic factors  
 
• Growth Factors  
 
• Structural molecules  
 
• Proteases [Digests connective tissue matrix (Clark, 1985)]  
 
 
 
ANGIOGENESIS OR NEO-VASCULARISATION : 
 
 
Vital part of proliferative phase of wound healing & repair. 
 
It is seen in18 
 
• Embryonic development phase  
 
• During repair process (throughout life span of an organism)  
 
• Under certain pathological conditions  
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Without Angiogenesis, invasion of the wound bed by macrophages & 
fibroblasts  would cease due to lack of oxygen & nutrients.18 
 
In the initial stages, these vessels lack the basement membrane & 
have loose cellular junction (Gullino, 1981) & are fragile in nature. Due to 
this, on slightest touch, the vessels bleed profusely which is a characteristic 
feature of newly formed capillaries. The leakage facilitates the movement of 
cells & macromolecules into wound site.18 
 
There are four steps in angiogenesis 18,19 
Step-I :  Proteolytic degradation of basement membrane of parent 
vessel to allow formation of capillary sprout & subsequent cell 
migration31 Angiogenic factors acts on capillary endothelial cells, which 
releases collagenase. This enzyme degrades the collagen of basement 
membrane.18 
Step-II:  Migration  of  endothelial  cells  towards  the  angiogenic  
stimulus 
Fragmentation of the collagen of basement membrane, permits the migration 
of endothelial cells into the peri-vascular spaces.18 
15 
 
 
 
 
Step-III: Proliferation of endothelial cells, just behind the 
leading front of migratory cells 
 
Endothelial cells migrate into the peri-vascular spaces where 
they form buds, which are added by the proliferation of cells with 
in & near parent vessel (Kalebie et al, 1983).18 
 
Step-IV: Maturation of endothelial cells & organization into 
capillary loops 
 
• Functional Capillary Loops: During dermal repair, these buds 
grow rapidly towards the free surface, where they branch at 
their tips & unite to form functional capillary loops.  
 
• Superficial Capillary Plexus : On these loops, new buds 
develop, so that, a superficial capillary plexus rapidly forms in 
the granulation tissue.  
• Canalization : Proliferation & branching of cords of 
endothelial cells later become canalized to form growing 
capillary buds of healing wound.  
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• Fusion : Capillaries originating from opposite sides of the 
wound fuse & establish a complete circulation with in the 
wound.  
REMODELLING OF THE VASCULATURE: 
 
There is constant remodeling of the vasculature, which 
involves obliteration of many of the capillaries (Marchesi, 1985). 
As each capillary loop becomes functional, it brings 
nutrients & oxygen to nearby cells, enabling the fibroblasts to 
secrete materials for the matrix, through which macrophages & 
other cells can migrate further. 
 
As the scar maturation proceeds, capillaries gradually 
regress & the red vascular rich wound tissue transforms into a 
white, relatively avascular cell poor scar (Zitelli, 1987) 
The above proliferative & migratory processes are repeated 
sequentially, until wound bed is filled with granulation tissue 
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MACROPHAGIA 18 
 
• It is a point at which protecting & clearing functions of 
inflammatory response are linked to starting of reparatory 
process  
 
What is Macrophagia? 
 
Macrophagia is 
 
[1] Migration of Monocytes [from blood] to tissue injury site  
 
 
[2] Conversion of monocyte to Macrophage after migration to 
tissue injury site. These are key cells in dermal repair  
 
• Wound macrophages, which appear subsequent to the cells, 
play pivotal role in healing by liberating various factors  
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FIG. 2.2: Functions of Microphages 
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Macrophages & angiogenesis18 
 
It appears that macrophages promote angiogenesis by liberating 
ENDOTHELIAL 
GROWTH FACTOR (EGF) 
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Macrophages & Collagenase Enzymes : 
 
Table 3.1: Role of Collagenase  
Phase of Sources of Role of collagenase 
wound 
healing collagenase  
   
In early part of Neutrophils 
Collagen of wound debris is broken down 
by 
wound healing  
collagenase & converted to breakdown 
products of 
  
collagen, which is then cleared by 
phagocytes, so, 
  they assist in tissue debridement 
   
In later part of Macrophages 
This enzyme controls the amount of new 
collagen 
wound healing  deposition. 
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Macrophages & Collagen: 
 
Macrophages secrete lactate which stimulates collagen synthesis by 
fibroblasts. 
 
Table 3.2 : Migration of Fibroblasts – Mechanism18 
 
Phase of 
Chemical which acts as chemotactic agent for fibroblasts in 
their 
inflammatio
n migration : 
  
Initial 
By Fibrin – Fibronectin – Collagen Scaffold of wound base 
(Brown et 
 al 1988) 
  
Later By : 
 [1]Soluble chemical factor from macrophages (Wahl, 1981) 
 [2]Collagen peptide (Postlethwait et al , 1978) 
  
 
 
Fig. 2.3: Functions of Fibroblast in Wound Healing 
 
How does number of fibroblasts increases at wound site ? 
 
 
[1] Influx of fibroblast [2] Active proliferation at the wound site 
from surrounding tissue 
 
Chemicals helping in active proliferation of fibroblasts at the 
wound site : -  
[A]Platelet Derived Growth Factor 
(PDGF)31 [B]Other factors from platelets 
[C]Macrophage derived growth factor  
[D]Activation of serum components by some other macrophage 
factors, which results in stimulation of fibroblast division. 
[E]TGF-beta (Transforming Growth Factor-Beta) 31  
[F]EGF31 
 
 
 
In vivo, the growth factors like- PDGF, TGF-beta, & EGF are part of an intricate network, which connects & co-
ordinates-Proliferation, Protein synthesis, & Chemo-tactic migration of fibroblasts (Adelmann Gill ET AL, 1990) 
21 
 
 
 
 
 
Fig 2.4 : Collagenation Mechanism 
 
 
When an organ or tissue is damaged 
 
 
 
Healing process starts & makes up the lost tissue. This healing takes place by:- 
 
 
Regeneration  Repair 
   
   
 
 
“It is a process of replacement of lost 
tissue by an identical type of fresh 
tissue”. There is proliferation of 
surrounding undamaged specialized 
cells.  
Seen in-  
[1] Epidermis  
[2] Endothelium  
[3] Liver cells  
[4] Mucous membrane  
 
 
“It is the replacement of lost tissues by 
granulation tissue, which matures to 
form the scar tissue”. 
 
 
 
The main component of scar tissue & 
newly laid connective tissue is collagen. It 
is suggested that , the repaired tissue 
may contain ≥50% collagen material, & 
hence this aspect of healing is referred to 
as collagenation (Peacock , 1984) 
 
 
 
Defects in collagenation can give rise to-  
[1] Weak scar (Poor Healing)  
 
[2] Contractures (Excessive Healing)  
 
[3] Hypertrophic scars (Excessive Healing)   
Therefore, an understanding of underlying bio-chemical, synthetic, & remodelling processes 
leading to the formation of collagen is essential for the rational approach to wound repair. 
Interruptions in the synthetic process & consequences of such interfere can provide knowledge 
for the clinicians with powerful tool to “Control Scar Formation” (Peacock, 1984). 
 
 
 
Collagen synthesis by fibroblasts begins early in wound healing, by 
day 03 or 05 & continues for several weeks, depending on wound site19 
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COLLAGEN FIBERS : 
 
Functions of collagen 19: 
 
1. Support to the tissues.  
 
2. Provides structural framework to other types of tissues.19  
 
3. Acts as a medium where blood vessels & nerves are passing.  
 
4. Bring & keeps the wound edges together & provides tensile strength 
for holding together This holding strength prevents the breakdown of 
tissue (organ) at the healed site.19  
 
5. Fill the gap caused by the tissue loss.  
 
• Collagen is the most abundant [25% of total body protein – Peacock, 
1984) proteins of the connective tissue.19  
 
Collagen is essentially a product of fibroblasts.  
 
• True fibrils form in the extracellular space & these collagen fibrils give 
strength to connective tissues.19  
 
• A critical extracellular modification is Lysyl Hydroxy-lysyl Oxidation. 
It causes cross linkage between alpha chains of adjacent molecules & is 
the basis of the structural stability of collagen. Cross linking is the 
major contributor to the tensile strength of collagen.20  
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• Collagen Deposition : Collagen that gets deposited into the extra-
cellular matrix of the healing wound has 4 successive phases of 
synthesis:  
 
1. Bio-synthesis of Tropo-collagen  
 
2. Fibril Formation  
 
3. Collagen Maturation  
 
4. Collagen Degradation.  
 
 
 
Types of collagen.19,21: On the basis of bio-chemical composition of the 
chains that make up the triple helix of the collagen molecule, some 14 types 
of collagen can be discerned, of which the most well characterized are 
shown in following table. 
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Table 3.3: Types of Collagen  
Type of 
CHAINS 
   Characteristi 
Distribution 
 
collagen    cs  
 
     Bundles of Skin (80%), Bone 
 
     banded fibers (90%),  Tendons, 
 
I α 1 (I), α 2(I)   with high Most other organs 
 
     tensile     
 
     strength     
 
     Thin fibrils, Cartilage (50%), 
 
II α 1 (II)    Structural Vitreous Humour 
 
     proteins     
 
     Thin fibrils, Blood  vessels, 
 
III α 1 (III)    Pliable  Uterus,  Skin 
 
       (10%)   
 
IV Α 1 Α 2 α 3 
α 4,α 5, Amorphous All basement 
 
α 6 (IV)   membranes 
 
 α 1    Amorphous, 2-5%  of      Fine fibrils interstitial tissues,  V [V, α  α3(V)       blood  vessels,   2(V)]              Interstitial tissues         
 
VI α 1 (VI) α 2 (VI) α3 (V)       
 
     Anchoring Dermal-   
 
VII α 1 (VII)    Filament Epidermal 
 
       Junction   
 
 α 1 Α 2   Probably Endothelium-  VIII   Amorphous Descement’s  
(VIII) (VIII)         Membrane         
 
IX α 1 (IX) α 2 (IX) α3  Probably Role Cartilage  
 
   (IX)  in  maturation    
 
X α 1 (X)    of cartilage    
 
  Α 2        
 
XI α 1 (XI) (XI), α        
 
  2 (XI)        
 
 
 
 
 
 
 
 
 
 
25 
 
 
 
 
DEGRADATION OF COLLAGEN AND OTHER ECM PROTEINS 
• Net collagen accumulation, however, depends not only on synthesis 
but also on collagen degradation.  
• Degradation of collagen and other ECM proteins is achieved by 
following enzymes.19  
Metalloproteinases.22 
• Helps in degradation of collagen and other ECM proteins  
• These are dependent on zinc ions for their activity.  
These enzymes are produced by.19 
• Fibroblasts  
• Macrophages  
• Neutrophils  
• Synovial cells  
• Some epithelial cells  
Their secretion is induced by 
• Growth factors (PDGF, FGF),  
• Cytokines (IL-l, TNF-a),  
• Phagocytic stimuli  
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• Nevertheless, it is thought that the collagenases play a role in 
degrading collagen in inflammation and wound healing.19  
• Degradation aids in the debridement of injured sites and also in the 
remodelling of connective tissue necessary to repair the defect.19  
• Indeed, collagenases and their inhibitors have been shown to be 
spatially and temporally regulated in healing burn wounds. 19  
 
 
GROUND SUBSTANCE IN HEALING WOUND18 
 
• Connective tissue consists of cellular and non cellular component 
(matrix). Matrix is again composed of fibres and ground substance.  
 
• Definition: This is non-fibrous part of the matrix in which cells and 
fibres are embedded.  
 
• Consistency: Except in mineralized connective tissue, the ground 
substance is a viscous gel.  
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Table 3.4: Constituents of Ground Substance  
Water High proportion 
  
Mucopolysaccharides 
It has been suggested that the fibroblasts, on the 
outer 
 
surface, have a layer of mucopolysaccharides 
(Peacock, 
 
1984c)  whose  charge  and  orientation  determine  
the 
 aggregation and orientation of tropocollagens. 
  
Fibronectin 
Fibronectin is a glycoprotein with high molecular 
weight 
 (Reese et at, 1983) 
 There are two types of Fibronectin 
 (a) Cell surface Fibronectin and 
 (b) Plasma Fibronectin 
 Functions: 
 
Fibronectin of connective tissue matrix acts as a 
glue 
 
between different matrix components and 
fibroblasts 
  
Chondronectin 
It is a specific adhesive between chondroblasts and 
type II 
 collagen 
  
Mucoproteins  
  
Glycoproteins  
  
Lamenin  
  
Entactin  
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WOUND CONTRACTION18 
 
• Definition: “Wound contraction may be defined as a process by which 
the size of the full thickness open wound is diminished by centripetal 
movement of the whole thickness of surrounding skin”.  
 
• The feature that most clearly differentiates primary from secondary 
healing is the phenomenon of wound contraction, which occurs in large 
surface wounds19  
 
• Wound contraction is one function of granulation tissue which is critical 
for repair.  
 
• The events of wound healing from injury to fibroplasias, occurs in 
almost all wounds. Certain events like wound contraction occurs 
characteristically in excision dermal wound and epithelization occurs in 
wounds of surface lining epithelium.  
 
• In humans, the wound contraction is less because in most parts of the 
body the skin is somewhat firmly attached to subcutaneous tissue but it 
can occur in areas like back of neck and buttocks (Peacock, 1984 ).  
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• Timing of Wound contraction:  
 
Wound contraction starts from about 3rd or 4th day of wounding 
and continues up to 15th or 16th day and stops thereafter, irrespective 
of whether the wound is totally closed or not. 
  
• Rate of wound contraction:  
 
  The rate of wound contraction is about 0.6-0.75 mm/day (Peacock 
1984).  
 
  Wound contraction is not materially affected by size or shape of the 
wound but perhaps by the length of the wound perimeter (McGrath 
and Simon, 1983).  
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• Mechanism of wound contraction 18:  
  The mechanism of wound contraction is disputable and debatable. 
Many theories like Pull theory, Push theory / Picture Frame theory 
etc have been proposed but none of them appears to be 
satisfactory.  
  Dollion (1987) pointed out that modified fibroblasts rich in actin 
filaments are responsible for wound contraction19  
  Myofibroblasts are situated just under the advancing edges of the 
wound.  
  In early phases of wound contraction, contractile epidermal cells in 
wound edges are suggested as a source of force (Baur et al, 1984).  
Wound contraction can be both beneficial or detrimental. Wound 
contraction can lead to distortion, disfigurement and impairment of 
function.  
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EPITHELIZATION18 
• Definition: Epithelization is a process of wound healing involving body 
surfaces.  
• Unlike healing by fibroplasias where lost parenchymal cells are replaced 
by non-specific connective tissue, in epithelialization lost epithelial cells 
are replaced by epithelial cells only. It is an example of healing by 
regeneration.  
• Stages of epithelization: The whole process of epithelization thus 
includes the following stages (Peacock,1984).  
  Mobilization and loosening of basal cells from their dermal 
attachment.  
  Migration or movement of cells to a position of cell deficit.  
  Proliferation or replacement of cells to a position of cell deficit and  
  Differentiation or restoration of cellular function.  
32 
 
 
 
 
 
 
 
• Epithelization which depends on several factors like:  
 
  Size of wound  
 
  Location of wound  
 
  Shape of wound  
 
  Impairement of blood supply  
 
  Pathological modification of wound.  
 
• Healing by epithelization occurs in:  
 
  Dermal wounds,  
 
  Wounds of tracheobronchial surface,  
 
  Surface wounds in gut, urinary bladder, uterus etc.  
 
• Timing of Epithelization:  
 
First 24 Hrs of injury :-Changes in the epidermis leading to re-
epithelization begin within 24 hours of the formation of a cutaneous 
wound.  
33 
 
 
 
 
Fig. 2.5: Mechanism of Epithelization 
 
'LEAP-FROG' hypothesis of epidermal regeneration (Winter,1962,1964) 
 
 
First 48 Hrs of injury 
 
 
Intact keratinocytes at 
the free edge of the cut 
epidermis begin to 
migrate across the 
defect. Migration 
process , called as 
EPIBOLY (Gabbiani et 
al, 1978). 
 
 
 
The basal keratinocytes of 
the new epidermis begin 
to divide, generating more 
cells capable of migration 
(Hell & Cruickshank, 
1963). 
 
 
 
If the injury is sufficient to 
disrupt the basement 
membrane, the keratinocytes 
migrate over a temporary 
matrix of fibronectin, fibrin 
and type V collagen (Clark et 
al, 1982; Repesh et al, 1982; 
Donaldson and Mohan, 
1983). 
 
 
 
Once migration ceases, the 
temporary matrix is replaced 
by basement membrane. 
 
 
Cells superficial to stratum 
basale at the edges of the 
wound elongate laterally and 
crawl over each other until they 
make contact with the wound 
bed, they then cease to move 
and begin to divide, producing a 
new supply of cells, some of 
which add to the thickness of the 
regenerating epidermis. 
 
 
 
Meanwhile other cells migrate 
over the first cells, reach the 
wound bed, divide and repeat the 
process in leap-frog fashion until 
prevented from doing so by 
contact inhibition. 
 
 
 
 
If migrating keratinocytes make contact with foreign particles 
 
 
Foreign particles of 
     
 Larger particles & dead tissues  Scab and eschar 
 
approximately 1 μm in          
 
      
 
Keratinocytes may remove 
them by phagocytosis, 
possibly after opsonization 
by fibronetin (Takashima 
and Grinnel, 1984 ). 
 
The keratinocytes 
migrates deep to any 
larger particles & dead 
tissues which lie in 
their path. 
 
Scab and eschar do not 
interfere with.epithelization 
because of the capacity of 
epithelial cells to secrete 
proteolytic and 
glycogenolytic enzyme 
which can pave their way 
underneath the scab 
(Marks, 1986). 
34 
 
 
 
 
WOUND HEALING19 
 
• MECHANISMS OF WOUND HEALING :  
 
Wound healing, as we have seen, is a complex (but orderly) phenomenon 
involving a number of processes, including induction of an acute 
inflammatory process by the wounding, regeneration of parenchymal 
cells, migration and proliferation of both parenchymal and connective 
tissue cells, synthesis of ECM proteins, remodeling of connective tissue 
and parenchymal components, and collagenization and acquisition of 
wound strength.  
• TYPES OF WOUND HEALING :  
 
  Primary union or healing by first intention - The healing of a clean, 
uninfected surgical incision approximated by surgical sutures. The 
incision causes death of a limited number of epithelial cells and 
connective tissue cells; as well as disruption of epithelial basement 
membrane continuity.  
 
  Secondary healing or healing by second intention  
 
 When there is more extensive loss of cells and tissue, as occurs in 
infarction, inflammatory ulceration, abscess formation, and surface 
wounds that create large defects, the reparative process is more 
complicated.  
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 The common denominator in all these situations is a large tissue 
defect that must be filled. Regeneration of parenchymal cells 
cannot completely reconstitute the original architecture.  
 
 Abundant granulation tissue grows in from the margin to complete 
the repair. This form of healing is referred to as secondary union 
or healing by second intention.  
 
Secondary healing differs from Primary healing in several respects: 
 
  Inevitably, large tissue defects initially have more fibrin and more 
necrotic debris and exudates that must be removed. Consequently, the 
inflammatory reaction is more intense.  
 
  Much larger amounts of granulation tissue are formed. When a large 
defect occurs in deeper tissues, such as in a viscus, granulation tissue 
with its numerous scavenger white cells bears the full responsibility 
for its closure, because drainage to the surface cannot occur.  
 
 
36 
 
 
  Perhaps the feature that most clearly differentiates primary from 
secondary healing is the phenomenon of wound contraction, which 
occurs in large surface wounds. Large defects in the skin of a rabbit 
are reduced in approximately 6 weeks to 5 to 10% of their original 
size, largely by contraction. Contraction has been ascribed, at least in 
part, to the presence of myofibroblasts-altered fibroblasts that have the 
ultrastructural characteristics of smooth muscle cells. The deposition 
of connective tissue matrix, particularly collagen, its remodeling into 
a scar, and the acquisition of wound strength are the ultimate effects 
of orderly wound repair.  
GROWTH FACTORS 
 Growth factors exert diverse effects on cell growth, metabolism, 
differentiation. Growth factors stimulate or inhibit progression through the 
cell cycle that Control cell viability or death, or that act principally to 
regulate cell differenciation.26 
Their modes of action include  
1. Autocrine  
Actions are mediated by a GF on its cell of origin after its secretion 
in to the extracellular environment.  
2. Paracrine  
GF that is secreted by one cell has an effect on adjacent cells. 
3. Juxtacrine   
GF  is bound to the cell membrane or extra cellular matrix. 
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4. Intracrine 
Actions occur inside the cell of origin. 
The effects of GF are mediated by activation of specific receptors. These 
receptors are transmembrane proteins.23,27 
The major growth factor families are 
 
Table 3.5 GROWTH FACTORS [23,28]  
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PLATELET DERIVED GROWTH FACTOR (PDGF) 
 
The wound environment contains a variety of growth factors. Platelet-
derived growth factor is of particular relevance due to its chemotactic, 
mitogenic,angiogenic, and stimulatory effects leading to matrix formation 
and wound bed granulation . PDGF may be of significant benefit of 
diabetics as recalcitrant diabetic wounds have been found to 
 
be deficient in or absent of PDGF.23 
 
Platelet-derived growth factor (PDGF) is one of the numerous  growth 
factors, or  proteins that regulate  cell growth and  division. In particular, it 
plays a significant role in  blood vessel formation (angiogenesis).PDGF was 
discovered as a protein released from the alpha granules of platelets. It was 
purified from platelets as a highly basic 30- kilo delton dimeric protein. 
Purified PDGF was found to consist of two related chains, PDGF- A, 
PDGF-B, products of separate genes. PDGF binds to two cell surface 
receptors, PDGFR-α and PDGFR-β which also are related in structure and 
sequence but are distinct gene products. Both growth and their receptors are 
expressed factors in a wide variety cell and tissue types. PDGF- has  been  
prepared and purified   
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STRUCTURE OF PLATELET-DERIVED GROWTH FACTOR 
 
 
Mature PDGF-A and -B chains are 109 amino acids in length and are 
60% identical. Both PDGF chains are synthesized as precursor proteins that 
undergo pro-cessing to yield mature glycoproteins. All three combinations 
of growth factor dimers have been isolated from tissues: AA, AB, BB in 
addition to platelet a granules, PDGF has been isolated from several cell 
types including macrophages and from aortic smooth muscle cells. Recently, 
two divergent members of the PDGF family were identified and termed 
PDGF-C and D.23 
PLATELET-DERIVED GROWTH FACTOR RECEPTORS AND 
SIGNALING 
The two PDGFRs are ligand-activated tyrosine protein kinases. The 
receptors are composed of an extracellular region that contains five Ig-like 
domains, a transmembrane segment, and an intracellular region with a 
tyrosine kinase domain that is split by a kinase insert of approximately 100 
amino acids. The binding of PDGF to the extracellular region of the receptor 
induces receptor dimerization.  
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Both homo- and heterodimets can form, depending on the ligand and 
the relative receptor abundance. PDGFR-β homodimers bind only PDGF 
BB and DD; PDGFR-α homodimers bind PDGF AA, AB, BB, and CC; 
whereas PDGFR-αβ heterodimers bind PDGF BB, AB, CC, and DD.23 
 
 
Fig 2.6 Structure of platelet derived growth factor receptors23 
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BIOI.OGIC EFFECTS 
 
PDGF action is essential for normal development. One of the major 
actions of PDGF in the adult is in wound healing. Tissue injury leads to the 
rapid release of abundant PDGF A or B by degranulating platelets. Other 
short-term sources of growth factor include activated macrophages and 
endothelial cells. It is chemotactic for smooth muscle cells, fibroblasts, 
neutrophils, and monocytes and stimulates macrophage activation. It is a 
potent mitogen for fibroblasts and smooth muscle cells and stimulates their 
proliferation in collaboration with other growth factors. PDGF induces 
expression of fibronectin, of collagenase, and of some types of collagen, and 
these proteins participate in the tissue remodelling that occurs during wound 
healing.23 
 
 
PLATELET  RICH  PLASMA(PRP):57 
 
 
Platelet-rich plasma (PRP) is an autologous product, with large number of 
platelets in a small volume of plasma. It is derived by centrifugation of the 
whole blood . PRP is effective in improving the natural way of wound 
healing, soft tissue and bone reconstruction . 
42 
 
 
PRP incorporates high concentrations of  fibrin,  PDGF, into the graft 
mixture.  Through recent studies, it has been learnt that PRP has wide uses  
in clinical wound healing. When added to small bony defects , PRP 
increases the bone density. In case of larger defects, it is used in 
combination with grafting material. 
 PRP56 can also be exogenously applied to soft tissues, as it promotes tissue 
sealing and wound healing. When PRP is used pre operatively, it decreases 
the hospital stay and the post operative need of blood and blood products. 
 PRP in recent times, has also found its application in the field of cellular 
therapeutics and tissue engineering. Platelet-rich plasma (PRP) is a ﬁbrin 
tissue adhesive. It is different  from ﬁbrin glue  by the high platelet content. 
The platelets has a  capacity to accentuate wound healing and osteogenesis. 
PRP accelerates the hemostatic cascade to a stimuli, and also antagonizes 
the steroidal effect of delay in wound healing. PRP produces  an  
antimicrobial effect, due to its high content of leukocytes.  
PRP can be used as an effective hemastatic agent. PRP enhances epithelial, 
epidermal and endothelial regeneration.  It promotes angiogenesis, collagen 
synthesis, soft tissue healing and reduces dermal scarring. 
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PRP which  has a  wide range of clinical healing applications in various 
fields such as, 
Miscellaneous clinical application of PRP:58 
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 PRP is very effective for diabetic  patients  having chronic non-healing 
wounds. PRP also acts as carrier for growth factors, and so increases 
vascularization of  tissue. 
PRP decreases incidence of postoperative and intraoperative bleeding at  
both recipient and donor sites. It promotes the stability of grafted tissue due 
to its adhesive property. 
PRP and FIBRIN GLUE :60 
 PRP involves taking 10ml  patient’s blood before procedure, centrifugation, 
and  activating the platelets, application of the gel to the site. The platelets is 
in  a reverse ratio to red blood cells opposite to naturally obtained clot. The 
healing is improved 2 to 3 times. 
PRP has to be differentiated  from ﬁbrin glues.  
PRP FIBRIN GLUE 
High concentration of platelets Low platelet concentration 
Less fibrinogen More fibrinogen 
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MECHANISMS OF ACTION 61-64 
 Hemostatic Response to Injury: 
After an injury, the released  subendothelial factors attract platelets and 
activate coagulation. Platelets produce factors such as thromboxane, 
adenosine, and serotonin, which stimulates coagulation and fibrin is 
produced. 
 Hemostatic plug is formed due to increased thrombin production and 
platelet activation. This reduces bleeding. This also aids the wound healing 
by thrombin-mediated cell activation and platelet- mediated angiogenesis. 
Primary hemostatic plug is formed by activation of platelets, through the 
production of  Vwf and fibrinogen that binds platelets to the vessel wall and 
to one another. 
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 Secondary hemostatic plug  results fromed by  the  action of thrombin , 
which is essential for the formation of  ﬁbrin. Then the platelets gets 
entrapped between them.  The balance of all components  determines the 
integrity of hemostatic plug . 
PRP closely resembles the final step of the coagulation process,  by the 
formation of a ﬁbrin clot. 
Growth Factors:65 
  PRP produces its effects via the release growth factors from alpha granules 
to accelerate  wound healing . This process begins within minutes, and 
ninety percent of the GF are secreted within one hour. This process 
continues for about 7 days. The rate of wound healing is directly 
proportional to the amount of platelets found in the site. 
 
 
 
47 
 
 
 
 
48 
 
 
 
Contraindications 
Though treatment with autologous PRP is risk free, following are few 
conditions where it must be used carefully, 
1. Coagulopathies 
2. Thrombocytopenia 
3. Anemia 
4. Hemodynamic instability 
5. Sepsis 
6. Unstable angina 
 So it becomes mandatory to evaluate the hematological inidices  in the pre-
treatment period for every patients. 
 PREPARATION OF ACTIVATED PRP: 
 Activated PRP is prepared by two methods, 
1. Manual double spin method 
2. Automated method 
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MANUAL DOUBLE SPIN METHOD:66 
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AUTOMATED DEVICES 
Various automated devices are available in the market for the production of 
activated PRP. Although time saving, these devices are expensive and also 
with unproven efficacy. 
 
CLASSIFICATION  OF  PLATELET  CONCENTRATES 
Based on the quantity of fibrin and leukocyte, PRP can be broadly classified 
under following categories,  
1. PRP-p( platelet –rich plasma-pure) 
2. PRP-L( platelet –rich plasma and leucocyte) 
3. PRF-p ( platelet –rich fibrin pure) 
4. PRF-L( platelet rich fibrin and leucocyte) 
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DIABETES MELLITUS 
 
Definition : 
 
“Diabetes 31-37 mellitus is characterized by chronic hyperglycemia 
with disturbances of carbohydrate, fat, and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both”. 
 
Cause of  hyperglycemia  may include: 
 
•  Insulin production decreased   
 
• Reduced glucose consumption 
 
• Raised glucose synthesis  
 
 
“Level of glycaemia at which diabetes specific complications occur 
rather than on deviations from population based mean” 
 
Classification31-37 
 
TYPE I 
 
Type Pathology 
 
 
I A   Autoimmune beta cell destruction  Insulin Deficiency 
 
 
I B Develop insulin deficiency by unknown mechanism causing 
destructive process of beta cells Lack immunologic markers 
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Type II 
 
 
 
• Decreased  insulin production  
 
•  Insulin resistance  
 
• Raised  glucose synthesis 
 
Various metabolic ,genetic modification leads to high blood sugar 
level in type 2 diabetes. 
 
 
Initial phase of abnormal blood  glucose is seen in DM as 
 
• Impaired fasting glucose (IFG)  
 
• Impaired glucose tolerance (IGT)  
 
Diagnosis 31-37 
 
The National Diabetic Data Group & World Health Organisation have 
issued a diagnostic criteria for DM-2 based on the following facts: 
 
• RBS ≥200 mgs / dL Or ≥11.1 m mol / L with symptoms of DM 
(Polyuria, Polydipsia, Weight loss)  
 
• FBS ≥126 mgs / dL or ≥ 7.0 m mol / L  
 
• 2 Hr Plasma Glucose (During Oral GTT) ≥ 200 mgs / dL or ≥11.1 m 
mol/L (Not recommended as a part of routine screening).  
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• Strong co-relation b/w ↑ FPG & ↑ HbA1c concentration but currently 
not recommended for the diagnosis of DM.  
 
 
Table 3.6: Diagnosis of Diabetes Mellitus 
 
Terms Definition 
  
Random Blood 
Glucose Blood Glucose levels not related to meals  
(RBS)  
  
Fasting Blood Glucose 
Blood Glucose levels when there is no caloric 
intake from 
(FBS) past 8 Hrs 
  
2 Hr Plasma Glucose 
The  test  should  be  performed  using  a  glucose  
load 
(During Oral GTT) 
containing the equivalent of 75 gms anhydrous 
glucose 
 dissolved in water 
  
 
 
Chronic Complications of DM 31-37 
 
Diabetes mellitus affects almost all the organs and caries high 
morbidity and mortality on a chronic basis. 
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Fig. 2.7: Chronic Complications of DM
 
 
 
 
• Increased duration of high blood glucose is related to chronic complication 
mostly recognized in fourth decade 
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• Patient with type 2 diabetes usually diagnosed with some complication due 
to asymptomatic high blood sugar levels for long time.  
 
 
• Chronic hype rglycemia leads to increased microvascular changes. 
 
• All pathies related to diabetes are prevented  by controlling the high 
blood sugar values.  
 
• Two to four times higher mortality was recognized in patient with 
chronic hyperglycemia is noted. 
 
 
• High HbAc1 ,fasting and postprandial blood sugar level are 
associated with above mentioned complication. 
 
 
• Increased lipid, and high blood pressure significantly contribute to  
macrovascular complications.  
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Mechanisms of complications 31-37 
 
Many Theory are proposed to relate high blood sugar value to   chronic 
complications of DM (Fig. 2.8). 
 
A hypothesis proposes that leading to : 
 
Fig. 2.8: Mechanisms of Complication of Diabetes Mellitus 
 
 
Hyperglycemia 
 
 
 
Increase flux through the hexosamine pathway 
 
 
 
Production of fructose-6-phoshate, a substrate for O-
linked glycosylation and proteoglycan production. 
 
 
 
The hexosamine pathway may alter function by  
• Glycosylation of proteins such as endothelial nitric oxide synthase   
• By changes in gene expression of transforming growth factor β (TGF- β)   
• Plasminogen activator inhibitor-l (PAI-l). 
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Neuropathy And Diabetes Mellitus 31-37 
 
• The incidence of neuropathy is 32 percent in middle age ,to that of  60 
years of age.1,2 where it is about 50 percent. 
 
 
•  Neuropathy is directly related to blood sugar , and duration of diseas. 
 
 
• May manifest as  
 
1. Polyneuropathy  
 
2. Mono-neuropathy  
 
3. Autonomic Neuropathy  
 
1.  Myelinated and unmyelinated  fibers are affected.  
 
 
2.  Diabetic neuropathy  is are  diagnosis if of other possible etiologies are 
excluded.  
 
Poly-neuropathy / Mono-neuropathy : 
 
• The symmetric polyneuropathy is common form of neuropathy in 
diabetes.  
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• It presents as:  
 
1. Distal sensory loss - most frequent presentation  
 
2. Hyperesthesia  
 
3. Paresthesia  
 
4. Dysesthesia  
 
• Symptoms includes a sensation of following, which begins in the feet 
& spreads proximally.  
1. Numbness,  
 
2. Tingling  
 
3. Sharpness  
 
4. Burning  
   
 
• Physical examination reveals  
 
1. Sensory loss  
 
2. Loss of ankle reflexes  
 
3. Abnormal position sense.  
 
 
 
• Worsening of lower limb Pain and rest pain is  typically seen in diabetes  
patients. 
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• Chronic and acute type of  painful , neuropathy have been described.  
 
 
•  As duration of disease  progress, neuropathy also progress in legs. 
 
• With improvement in the sugar value, progression of neuropathy 
decreases. 
 
 
 
 
Diabetic Neuropathy : 
 
It may be accompanied by - Motor weakness 
 
 
Definition-“It is a syndrome characterized by severe 
disabling pain in the distribution of one or more nerve root” 
 
 
 
 
Intercostals or truncal radiculopathy 
 
 
 
 
Pain over thor 
 
 
 
 
Involvement of lumbar plexus or femoral nerve 
 
 
 
 
Pain in hip & or thigh& may be assc with muscle 
weakness in the hip flexors or extensors 
(diabetic amyotrophy) 
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Treatment of diabetic 
neuropathy :   
 
• Symptomatic treatment.  
 
• Since pain of acute diabetic neuropathy may resolve over the first 
year,analgesics may be discontinued as progressive neuronal damage 
from DM occurs.  
• Chronic, painful diabetic retinopathy is difficult to treat but may  
 
respond to 
 
1. Tricyclic antidepressants - Amitryptiline, desipramine, nortriptyline  
 
2. Gabapentin  
 
3. NSAIDs (Avoid in renal dysfunctions)  
 
4. Others (Mexilitine, Phenytoin, Carbamazepine, 
Capsaicin cream) Referral to pain management center may be 
necessary.  
 
Lower Extremity Complications 31-37 
 
• Foot ulcers and infections are a major source ofmoibidity in individuals 
with DM.  
 
• The reasons for the increased incidence of these disorders in DM involve 
the interaction of several pathogenic factor?  
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• Neuropathy  
 
• Abnormal foot biomechanics  
 
• Peripheral arterial disease  
 
• Poor wound healing.  
 
Neuropathy : 
 
Neuropathy is present in over 80 percent of patients with foot ulcers. 
 
Peripheral sensory neuropathy : 
 
Interferes with normal protective mechanisms and allows the patient 
to sustain major or repeated minor trauma to the foot, often without 
knowledge of the injury 
 
Motor and sensory neuropathy : 
 
Lead to abnormal foot muscle mechanics and to structural changes in 
the foot (hammer toe, claw toe deformity, prominent metatarsai heads, 
Charcot joint). 
 
Autonomic neuropathy : 
 
Results in anhidrosis and altered superficial blood flow in the foot, 
which promote drying of the skin, and fissure formation. 
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Peripheral arterial disease and poor wound healing : 
 
Impede resolution of minor breaks in the skin, allowing them to 
enlarge and to become infected. 
 
 
Disordered proprioception : 
 
Causes abnormal weight bearing while walking and subsequent 
formation of callus or ulceration. 
Approximately 15% of individuals with DM develop a foot ulcer, 
and a significant subset will ultimately undergo amputation (14 to 24%) 
risk with that ulcer or subsequent ulceration. 
 
 
VASCULAR CHANGES IN DIABETES 
 
1. Atherosclerosis: Chronic inflammatory process that can be converted into 
acute clinical event by plaque rupture38,39. 
 
Development of atherosclerosis is accelerated in DM leading to 
increased morbidity and mortality. All the large vessels are involved in this 
process and clinical manifestations are apparent as a result of atherosclerotic 
narrowing and thrombosis of coronary, cerebral and leg vessels 
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І. Lipoproteins pathogenesis:40,41 
 
Fig 2.9: Pathophysiology diabetic vasculopathy 
 
Diabetes Mellitus 
 
LDL transport across vessel wall 
 
Trapped by cellular matrix of sub endothelial space 
 
Oxidation 
 
Chemotactic factors released 
 
Monocyte chemo-attractant proteoin 
 
Further oxidation of LDL 
 
Cytotoxic LDL 
 
Not recognized by receptor 
 
Taken up by macrophages 
 
Formation of foam cells 
 
‘Attract smooth muscles from media to 
intima Fibro-fatty plaques 
Narrowing of vessels 
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П. Endothelium: 
 
a. Nitric oxide, (NO): (EDRF-Endothelium derived relaxing factor) 
 
Nitric oxide, (NO)42        
 
      
 
  
 Nitric oxide, (NO)  Changes in retinal      
        circulation          
 
↑se Collagen synthesis  Regulates polyol pathway    
 
         
 
         
 
Accumulation in Kidney  
Neuropathy 
  
 
      
     
 
      
Nephropathy    
 
b. Prostacyclin (PGI2)
43        
 
   PGI2   
 
 
Potent vasodilator also inhibits 
 
Platelet adhesion & aggression 
 
 
 
 
Prostacyclin stimulating factor 
(Present in human arterial smooth muscle) 
 
 
↓se in Diabetics & arterial wall of patients with old MI 
 
c. Thromboxane A2(TX-A2):>>>>Vasoconstrictor- Conteracts effect of N.O 
↑sed levels found in DM, HTN & hyperlipidemia.  
d. Endothelin::>>>>Vasoconstrictor  
 
↑sed levels found in DM around 3.5 times 
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Fig 2.10 Pathogenesis of diabetic ulcers.44-46 
 
Diabetes Mellitus 
 
Neuropathy & limited joint mobility 
 
Atrophy of intrinsic muscles & clawing 
 
Pressure transfer from heel & toes to metatarsal heads 
 
No redistribution of pressure 
 
Ulceration 
 
 
Predisposing factors for ulceration: 47 
 
1) Limited joint mobility.  
 
2) Peripheral neuropathy.  
 
3) High plantar pressure.  
 
4) Vascular diseases.  
 
 
Biomechanics of diabetic foot 47 
 
Gait cycle: 
 
1. Stance phase  
 
2. Swing phase  
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Fig 2.11 Biomechanics of diabetic foot 
 
Stance phase 
 
 
 
 
Contact phase Mid-stance phase Propulsive phase 
 
 
 
 
To toe off Opposite toe off   Active propulsion Passive lift off 
 
opposite Limb forefoot loading 
 
And heel lift 
 
 
 
 
Plantar flexion 
Dorsiflexion ( 
max Heel lift off 
Opposite heel 
contact 
 Pressure on 
supporting side 
& & terminates with 
 forefoot) 
ends with 
opposite supporting side 
  side heel strike toe off 
 
 
 
Changes in foot caused by diabetes 
 
1. Peripheral neuropathy 48  
 
A. Dryness of skin  
 
B. Callus formation  
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2.  High pressure at bony prominences 
 
↓se plantar tissue thickness 
 
 
 
 
Weak intrinsic muscles of foot 
 
 
 
 
Imbalances of flexors & extensors causing clawing of foot 
 
 
 
 
Pulling away fat padding from metatarsal heads 
 
 
3 Limited joint mobility 49 
 
Unknown etiology 
 
Collagen abnormality 
 
Thickening of skin tendons & joint capsules 
 
Decreased tissue flexibility 
 
Increased plantar pressure 
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4  Trauma 50,51 
 
Trauma 
 
 
 
 
Intrinsic Extrinsic 
 
 
 
 
Repetitive stress from high pressure / Callus Ill-fitting footwear 
 
 
 
 
Fig 2.12: Causation of ulceration.52,53  
Pressure 
 
 
 
 
Duration ↑se magnitude           Repetitions of pressure 
 
 
 
 
Relatively low High pressure Foot slap Mechanical fatigue 
 
Pressure for acting for short  of tissues 
 
longer periods duration 
Weak dorsiflexion 
 
 
   
 
Ischemia   Loss of tissue 
 
  ↓se deceleration integrity 
 
  of forefoot  
 
Cell death   Breakdown 
 
  Rapid strike due to  
 
Wound  ↑se velocity 
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CLASSIFICATION OF DIABETIC FOOT ULCERS.54 
   
Several foot ulcer classification schemes have been proposed, but none 
is universally accepted. The six grade Wagne- Meggit classification, which 
has been used for decades, classifies wounds by the depth of ulceration and 
extent of gangrene. The International Working Group on Diabetic Foot has 
proposed the PEDIS classification, which grades the wound on the basis of 
five features: 
 
• Perfusion (arterial supply)  
 
• Extent (area)  
 
• Depth  
 
• Infection  
 
• Sensation  
 
 
 
WOUND DRESSING IN DIABETIC FOOT 
 
The management of wound and wound dressing is an important aspect 
of diabetic foot management. Proper dressing with cost effective dressing 
material, done with scientifically correct method can help in salvaging 
diabetic foot. The various functions of the dressings are: 
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• Isolation of the wound from external environment.  
 
• Limit/reduce tissue oedema.  
 
• Reduce pain.  
 
• Improve gas exchange between tissues and blood.  
 
• Limit inflammation.  
 
• Absorb exudate.  
 
• Should not promote bacterial growth.  
 
• Prevent dessication and contamination.  
 
 
 
All the dressings can be classified as primary or secondary. Primary dressing 
is the one, which is in direct contact with the wound. Secondary dressing is of 
the material, which holds the primary dressing in place. It has function of 
compression, occlusion and additional protection. 
 
VARIOUS TYPES OF DRESSINGS 
 
A wide variety of dressing materials are available for dressing of 
infected diabetic foot ulcers. 
 
1. Eusol: contains bleaching powder and boric acid. Acts by chemical 
desloughing of the wound.  
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2. Collagenase dressing: contains collagenase enzyme which helps in the 
break down of devitalized tissues  
3. PDGF gel: contains platelet derived growth factor. Causes 
angiogenesis and leads to formation of healthy granulation tissue  
4. Comupimet ointment: contains collagen crystals with Mupirocin and 
Metranidazole. Acts by enhancement of granulation tissue along with 
antibacterial action  
5. Aquacell: contains silver ions, which has anti microbial action. Helps 
in cleansing the wound.  
6. Biological dressings-  
 
a) APLIGRAFT- Bioengineered skin  
 
b) DERMA GRAFT- Human dermis  
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METHODOLOGY 
 
 
Study design: Randomized controlled trial 
 
Source of Data : Patients with diabetic foot ulcers admitted in surgery wards 
at Stanley medical  college hospital, Chennai . 
 
Sample Size : 
 50 patients 
 25-patients -in the study group 
 25-patients -in the control group 
Inclusion criteria 
1. Type I and II Diabetes mellitus. 
2. Diabetics between 12 to 75 years of age. 
3. Have documented wound etiology resulting from complications of DM 
4. Duration of the ulcer more than 4 weeks. 
5. Size of ulcer less than 10x10 cm 
6. Fasting blood glucose levels measured in two occasions 24 hours  
apart between 140mg/dl- 200mg/dl  
 
 
74 
 
Exclusion criteria: 
1 Pulseless limb  
2 Immunocompromised patients  
3 Associated osteomyelitis.  
4 Skin malignancy  
5 Cellulitis  
6 Diabetic Ketoacidosis. 
7 Exposed  bone and tendon in ulcer. 
 
Method 
The present study was  carried   out in Stanley Medical College  
Hospital, Chennai.  where 50 patients with diabetic foot ulcers participated  in 
the present  study. Using a pretested  and  predesigned  proforma was 
randomized  into either study group or control group population using 
randomization chart.  
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DRESSING TECHNIQUE 
 
For conventional dressing. 
 
The ulcer was cleaned with normal saline and saline soaked gauze 
piece was kept over the ulcer which was covered with pad and roller 
bandage. 
 
Study group: 
Patient in study group is treated with PRP .Platelet rich plasma is made 
manually by drawing 10 ml of blood by venipuncture.5ml of blood is put in a 
two test tube each ,and adding anticoagulant citrate dextrose 
(ACD).centrifuge for 10 minutes at 2000 rotation  per minute. Three  layers 
obtained as, top layer plasma, middle layer buffy coat ,RBC at the bottom 
.Plasma and the buffy coat layer was separated by pippet, and put in test tube 
mixed with calcium chloride (cacl2) .Second centrifugation done for 10 
minutes at 2000 rotation per minute. It resulted in three layers, as top platelet 
poor plasma (PPP),platelet rich plasma and at bottom , RBC. 
The platelet poor plasma is discarded and platelet rich plasma is 
separated and taken in syringe, which is injected in wound site. This platelet 
rich plasma dressing is done biweekly for four weeks and ascessed for wound 
contracture. 
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CENTRIFUGE 
 
VENIPUNCTURE 
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BLOOD COLLECTED IN TEST TUBE WITH ACD 
 
AFTER FIRST CENTRIFUGE 
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AFTER SECOND CENTRIFUGE 
 
PRP INJECTED IN WOUND SITE 
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BEFORE        AFTER 
 
 
 
 
 
 
BEFORE     AFTER 
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 OBSERVATIONS AND RESULTS  
  Table 4.1: Age Distribution  
      
Age (Years)  No. of Cases  Percentage  
      
18-30  0  0%  
      
31-40  06  12.00%  
      
41-50  09  18.00%  
      
51-60  23  46.00%  
      
> 60  12  24.00%  
      
Total  50  100  
      
 
 
In our study it was observed that Diabetic foot was commonest in the age 
group between 51-60 yrs of age
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Table 4.3 : Sex Distribution 
 
Sex No of Cases Percentage 
   
Male 33 66.00% 
   
Female 17 34.00% 
   
Total 50 100. 
   
 
 
In our study in was observed that Diabetic foot was more common in the 
males (66.00%) as compared to females (34.00%) 
 
 
Table 4.4: Site of ulcer in the study 
 
Site No. of Cases Percentage 
   
Plantar 31 62.00% 
   
Dorsum 19 38.00% 
   
Total 50 100% 
   
 
 
In our study it was observed that diabetic foot more commonly occurs 
on the plantar aspect (62.00%) of the foot as compared to the dorsal aspect 
(38.00%) 
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Table 4.5: Onset of Diabetic Foot Ulcers 
 
Type of Onset No of Patients Percentage 
   
Traumatic 32 64.00% 
   
Spontaneous 18 36.00% 
   
Total 50 100 
   
 
 
Trauma is the most common cause of diabetic foot ulcer (64.00%) while only  
36.00%were spontaneous in origin. 
 
 
Table 4.6 : Anti Diabetic Agents 
 
Anti Diabetic No. of cases Percentage 
   
OHA 11 22.00% 
   
Insulin 39 78.00% 
   
Total 50 100% 
   
 
 
In our study most of the participants were taking Insulin for glycaemic 
control. 
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Table 4.7 : Wound Contraction 
 
Group Mean Red% S.D. Median P Value 
     
Control 13.52% 2.55 13.20  
     
Study 34.42% 2.52 34.58 P<0.001 
     
 
 
In our study it was observed that Mean % of area reduction was higher in 
study group (34.42%) as compared to the controls (13.52%). 
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STATISTICAL ANALYSIS 
 
 
Statistical analysis was done by using Microsoft EXCEL software and 
SPSS computer program. 
Diabetic foot ulcers in the study group had better mean % of wound 
contraction of 34.42% (S.D; 2.52: Median; 34.58) as compared to the control 
group which had mean % of wound contraction of 13.52 % (S.D; 2.55: 
Median; 13.20), the difference in the mean 20.90% of area reduction of the 
two groups where studied using unpaired student t test was found to be 
significant (p<0.001). 
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DISCUSSION 
It is every surgeon’s desire that after dressing the wound, it should 
heal without any complications. Successful wound dressing should keep the 
wound moist and be devoid of any adverse reactions such as infection, 
maceration and allergy. Diabetic foot ulcers are chronic wounds, stuck in 
inflammation phase and shows cessation of epidermal growth 
The present study was conducted at Stanley medical college hospital, 
chennai to study the effect on chronic diabetic wound healing dynamics 
In the present study it was seen that the incidence of diabetic foot 
ulcers were more in males (66.00%) as compared to females (34.00%). 
The second national data source, NHDS documented higher hospital 
rates in males suffering from diabetic foot ulcer. 
Diabetic foot ulcers are most commonly seen in 6th decade (60%), the 
next common being in the fifth decade (20%). While only 11.25% of the 
patients were in the fourth decade. Older the patient more the chances of 
having diabetic foot ulcer. The prevalence of diagnosed diabetics increases 
with age (the diabetic foot). In this study patients with vascular 
complications such as pulse less limb and the patients with osteomyelitis 
were excluded. 
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In this study, 64.00% of the ulcers were traumatic in origin, trauma 
being the triggering factor secondary to neuropathy. 36.00% were 
spontaneous in origin secondary to blister rupture or unnoticed trivial 
trauma. 
More than half (62.00%) of the patients had ulcer on the plantar 
surface of the forefoot and the remaining (38.00%) had on the dorsum of 
foot. Study conducted by Edmonds et al in 1986, (Edmonds) showed more 
foot ulcers were on plantar and fore foot areas. Most of the diabetic foot 
ulcers are invariably shoe related and due to gait abnormalities. They can be 
prevented by appropriate sized footwear. However in our study the incidence 
of ulcers over the plantar aspect of the foot were not as high as postulated by 
Edmonds et al. 
Most of the patients (78.00%) were on insulin for control of sugar 
whereas only 22.00 % were on Oral Hypoglycaemic Agents. 
In our study it was observed that participants receiving PRP  dressing 
had better wound contraction of 34.42% (S.D; 2.52: Median; 34.58) As 
compared to the group receiving only conventional dressing (normal saline 
dressing) in whom the mean wound contraction was 13.52% (S.D; 2.55,  
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Median; 13.20), these were found to be statistically significant on unpaired 
Student t test (p<0.001) suggesting that PRP dressing enhances wound 
healing in diabetic wounds. 
 
Feasibility of this study: 
 
In the present study we have taken 50 patients suffering from Diabetes 
Mellitus with foot ulcers. Patients were taken up for study based on 
inclusion and exclusion criteria. Out of 50 patients, 25 ( 18 males, 07 
females) were study cases and 25 ( 15 males and 10 females) were control. 
Participants included in the study group were treated with the PRP dressing 
biweekly for four weeks. All 25 patients selected for PRP treatment 
complied for the four weeks period of the study. The initial area 
measurement was taken on first week and final area measurement on fourth 
week was taken on transparent sheet. 
All 25 patients selected as a control complied for the four week 
duration period of the study. The initial area measurement on first week final 
area measurement on fourth week was taken on transparent sheet.  
 
96 
 
 
 
We have applied the following formula to calculate % reduction in 
area of wound after four weeks period in both cases and control groups. 
Rate of contraction of wound after four weeks of treatment = 
 
(Initial area – Final Area)  
X 100 
 
Initial area 
 
 
We have found 13.52% (S.D; 2.55 : Median; 13.20 ) contraction of 
wounds in the control groups as compared to 34.42% (S.D; 2.52 , Median; 
34.58) contraction of wounds in study group. Therefore, study groups are 
having % more wound contraction as compared to control group. On 
applying unpaired student t test p<0.001 which is significant. 
From our study, we can say that PRP dressing therapy facilitates 
wound healing in patients suffering from diabetes mellitus. 
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Limitations of our study: 
1. Follow up is short to derive conclusion on long term healing of the 
ulcers.  
2. The cost involved was not analyzed in this study.  
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CONCLUSION 
 
The wounds in subjects treated with PRP dressing contracted more 
than the wounds in the non treated group (34.42% Vs 13.52%; P = < 
0.001 Significant) which indicates PRP dressing is an effective modality 
to FACILITATE wound contraction in patients suffering from diabetes 
and can be used as an adjunct to conventional mode of treatment 
(conventional dressings and debridement) for healing of diabetic wounds. 
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SUMMARY 
 
 
 
The incidence of diabetes and complications are on rise. Diabetic foot 
being one of the most common complications, where 15% of all diabetics 
develop diabetic ulcers, the most common site being the foot. Diabetes has 
highest risk factor associated with limb threatening ischemia. Trivial trauma 
secondary to neuropathy and distorted pedal architecture causes ulcerations. 
15% of all diabetics develop foot ulcer. 20% of admissions in diabetics are 
for foot problems. 
Various modalities of treatment have been developed to aid faster 
healing of diabetic foot ulcers. Course of healing in diabetic foot patients is 
unpredictable and resistant to treatment. 
50 patients of diabetic foot ulcers were studied. They were divided into 
two groups of 25 each. 
 
 
100 
 
 
One group received PRP and the control group received treatment in 
the form of conventional therapy. A comparative study was done between 
both groups regarding percentage area wound reduction. 
Patients were between 51-60 years of age, Males were more affected 
than females. 66.00% males Vs 34.00% females. 64.00% of the ulcers were 
traumatic in onset. Plantar aspect (62.00%) was most common site. 
Most of the patients were on insulin (78.00%) compared to the oral 
hypoglycaemic agents (22.00%)  
All patients in the study underwent X-ray of the affected foot, patients 
with stress fractures and osteomyelitis were excluded. 
In our study it was observed that participants receiving PRP had better 
wound contraction of 34.42% as compared to the group receiving only 
conventional treatment in whom the mean wound contraction was 13.52%, 
these were found to be statistically significant on unpaired Student T test 
(p<0.001) suggesting that PRP enhances wound healing in diabetic wounds. 
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Thus, PRP dressing therapy in the treatment of diabetic foot ulcers 
was found to be more effective, safe, promoter of wound healing, and hence 
can be recommended for the treatment of diabetic foot ulcers as an adjuvant 
to the conventional mode of treatment. 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
1. Principles of Internal medicine- Harrison’s 15th edn. Vol 2, Chapter 333, Pg. 
2109-2111  
 
2. Most RS, Sinnock P. Epidemiology of lower extremity amputation in diabetic 
individuals. Diabetes Care. 87(91) : 1983  
3. Lehto ST, Ronnemaa T, Pyorala K. Risk factors predicting lower extremity 
amputation in patients with NIDDM. Diabetes Care 1996; 19:607.  
4. Seshian V and Venkataraman S. Aetiopathogenesis and management of diabetic 
foot, current concepts in DM, Ed. Saini GS and Talwalkar P, Typographics, 
1993; 88-97  
5. King H. Global burden of diabetes 1995-2025, Diabetes care, 1999(Asian 
edition); 1:233-250  
6. Mulder GD .Diabetic foot ulcers; old problems – new technologies Mulder 
16(4):695.  
7. Wieman TJ, MD, FACS, Janice MS, MD, Yachin Su. Efficacy and safety of a 
topical gel formulation of recombinant human platelet derived growth factor-BB 
(Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes 
care.1998 May;21(5):822.  
 
 
 
 8. Martin CR, Payne G W, Garner L W. Integrating  the  results  of  phase  IV (post 
marketing) clinical trial with four previous trials reinforces the position that 
regranex (Becaplermin) gel 0.01% is an effective adjunct to the treatment of 
diabetic foot ulcers. The journal of applied research.2005;5(1):36 
9. Embil J M, Papp K, Sibbald G, Tousigant Jr, Smiell J M, Wong B et al. wound 
repair and regeneration, vol 8 no 3 june 2000, pp 162-168(7).  
10. Robson MC, Thompson A, Pierce GF , Phillips LG, Robson LE: Platelet derived 
growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23-
25,1992  
11. Steed DL, the diabetic ulcer study group: clinical evaluation of Re combinant 
human platelet derived growth factor for the treatment of lower extremity 
diabetic ulcers. J Vasc Surg21:71-81, 1995  
12. Lynch SE, Colvin RB, Antiniades HN. Growth factors in wound healing: single 
and synergistic effects on the partial thickness porcine skin wounds. J Clin 
invest. 1989;84:640-646.  
13. Pierce GF, Mustoe TA, Lingelback J. Platelet derived growth factor and 
transforming growth factor—B enhance tissue repair activities by unique 
mechanisms. J Cell Biol 1989;109:429- 440.  
14. Watkins P J ; ABC of diabetes, The diabetic foot; British Medical Journal; May 
2003 vol. 326, 977-979  
15. Joslin’s Diabetes Mellitus – 13th edition by Ronald Kahn, Gordon Weir- 1996  
 
 16. Pati S, Sauandal BK, Bhattacharyya AR, Bhattacharyya AK., P Saumandal; 
Clinical Evaluation of Effect of Dressing with Placental Extract in the treatment 
of Infected wounds; Indian journal of obgyn; may-june 2001,  
17. Sabiston textbook of surgery, 17th edn vol.(1): 183  
18. Maiya GA; Kumar P; Rao L; Photo Medicine and Laser Surgery; Effect of Low 
Intensity Helium-Neon (He-Ne) Laser Irradiation on Diabetic Wound Healing 
Dynamics; April 2005, Vol 23(2) : 187-190.  
19. Cotran R, Kumar V, Robbins S, 1994 ; 5th (ed.), W. B. Saunders company.  
20. Krieg T. Molecular defects of collagen metabolism in ehlers-danlos syndrome. 
Int. J. Dermatol. 20: 415, 1981.  
21. Lingenmayer, T.F.: Collagen. In Hay, E. (ed.): Cell BLology of the Extracellular 
Matrix, 2nd ed. New York, Plenum Press. 1992, 7-44.  
22. Matrisian, L.M.: The matrix-degrading metalioproteinases. Bioassays 14: 455, 
1992  
23. Rotwein P. Peptide growth factors other than Insulin like growth factors or 
cytokines, 675-690  
24. Sporn MB, Roberts AB: Peptide growth factors are multifunctional. Nature 
332;217-218, 1998  
25. Keating MT, Williams LT: Autocrine stimulation of intracellular PDGF 
receptors inv-sis-transformed cells. Science 239: 914-916, 1998  
26. Matsui T, Heidaran M, Miki T,Isolation of novel receptor cDNA  
 
27. Dahn MS. The role of growth factors in wound management of diabetic foot 
ulcers.  
28. Federal Practitioner 1998; July, 14-19.  
 
29. Robson MC: Exogenous growth factor application effect on human wound 
healing. Progress in Dermatology. Editor Alan N.  
30. Beer H S, Longakar M T, Wernar S. Reduced expression of PDGF and PDGF 
receptors during wound healing.  
31. Greenhalgh D G, Sprugel K H, Murray M J, Ross R. PDGF and FGF stimulate 
wound healing in the genetically diabetic mouse.  
32. American diabetes association: Clinical practice recommendations 2002. 
Diabetes Care 27: 51, 2004.  
33. Clement S et al: Management of diabetes & hyperglycemia in hospitals. Diabetes 
Care 27: 553, 2004.  
34. Kirpichnikov D et al: Metformin: An update, Ann intern med 137: 25, 2002  
 
35. Knowler WC etal for the Diabetes prevention program research group: 
Reduction in the incidence of type-2 diabetes with lifestyle intervention of 
metformin. N Engl J Med 346: 393, 2002.  
36. Saltiel AR, Kahn CR: Insulin signaling & the regulation of glucose & lipid 
metabolism, Nature 414: 799, 2001.  
37. The writing team for the diabetes control & complications trial/ Epidemiology of 
the diabetes interventions & complications research group: Effect of intensive 
therapy on the microvascular complications of type-I Diabetes mellitus. JAMA 
287: 2563, 2002.  
38. UK Prospective diabetes study group: Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment & risk of 
complications in patients with type-2 diabetes (UKPDS 33). Lancet 352: 1998, 
1998.  
 
39. Levin and O’Neals – The Diabetic foot – VI Edition 4:65-106, 2001.  
 
40. Berliner JA, et al : Atherosclerosis Basic mechanics, Oxidation, Inflammation 
and genetics, Circulation 91;2488-2496, 1995  
41. Gisinger C, Vivella GT, Lopes, Vivella MF: Erythrocyte bound low density Lipo 
protein immune complexesniead to cholesterol accumulation in human monocyte 
derived macrophages. Clin Immunol- Immunopathol 59:37 – 52, 1991  
42. Griffith RL, et al, LDL metabolism by macrophages activated with LDL immune 
complexes: A possible mechanism of foam cell formation J. Exp med 168: 1041-
1059, 1998  
43. Ignaro L J, et al : Endothelium derived relaxing factor produced and released 
from artery and vein is nitric oxide. Proc NaH Acad Sci USA 84: 9265, 1987  
44. Moncada S: Biological importance of prostacyclin, Br. J. Pharmacol 76:3, 1982  
 
45. Cavanagh PR, Simoneau GG, Ulbreech T JS: Ulceration, unsteadiness and 
uncertainity; The biomechanical consequences of DM. J Bio mechanical, 26 
(suppl: 1); 23-40, 1993  
46. Frykerg RG: Biomechanical considerations of diabetic foot Lower extremity 
2:207-214, 1995  
47. Frykerg RG, Lavery LA, Pham H, et al, Role of neuropathy and high foot 
pressures in diabetic foot ulceration; Diabetic care 21; 1714-1719, 1998  
48. Payne CB: Biomechanics of the foot in DM: some theoretical considerations. J 
Am Podiatr med Assoc 88: 285-289, 1998  
49. Boulton AJM, Late sequelae of diabetic neuropathy, Marios Press, Carnferth, 
Lancashire, UK, 1997, PP.6376  
 
50. Fernando DJS, Masson EA, Veves A, Boulton AJM: Relationship of limited 
joint mobility to abnormal foot pressures and diabetic foot ulceration. Diabetes 
care 1991; 14:8- 11  
51. Tooke JE, Brash PD, Microvascular aspects of diabetic foot disease, Review 
diabetic med 13(suppl. 1) : 526-529, 1996  
52. Delbridge L, Ctercteko G, Flower C et al – Etiology of diabetic neuropathic 
ulceration of the foot. Br. Journal of surgery 72: 1-16, 1985  
53. Davis BL: Foot ulceration: Hypothesis concerning shear and vertical forces 
working on adjacent regions of skin; med Hypothesis 40:44-47, 1993  
54. Cavanagh PR, Morag E, Boulton AJM et al. Relationship of static foot structure 
to dynamic foot function, J Biomech 30:243-250, 1997  
55. Peter R Cavanagh, Benjamin A Lipsky, Andrew W Bradbury, Georgeanne 
Botek; Treatment for diabetic foot ulcers; The Lancet November 2005.  
56. Everts PA, Knape JT, Weibrich G, et al. Platelet-rich plasma and platelet gel: a 
review. J Extra Corpor Technol 2006;38:174-187. 
57. Marx RE. Platelet-rich plasma: Evidence to support its use. J Oral Maxillofac 
Surg 2004; 62:489-496. 
58. Knighton DR, Hunt TK, Thrakral KK, Goodson WH. Role of plate- lets and ﬁ 
brin in the healing sequence. Ann Surg 1982;196:379-388. 
59. Landesberg R, Burke A, Pinsky D, et al. Activation of platelet-rich plasma using 
thrombin receptor agonist peptide. J Oral Maxillofac Surg 2005;63:529-535. 
60.  Man D, Plosker H, Winland-Brown JE. The use of autologous plate- let-rich 
plasma (platelet gel) and autologous platelet-poor plasma (ﬁ brin glue) in 
cosmetic surgery. Plast Reconstr Surg 2001;107:229-237. 
61.  Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts, 
osteomies, and implants ﬁ xation. ACTA Orthop Scand 1998; 283:2-37. 
62.  Marx RE. Platelet-Rich Plasma: A Source of Multiple Autologous Growth 
Factors for Bone Grafts. In: Lynch SE, Genco RJ, Marx RE, eds.  Tissue 
Engineering: Applications in Maxillofacial Surgery and Peridontics. Chicago: 
Quintessence Publishing Co, Inc.; 1999; 71-82.  
63. Kassolis JD, Reynolds MA. Evaluation of the adjunctive beneﬁ ts of platelet-rich 
plasma in subantral sinus augmentation. J Craniofac Surg 2005;16:280-287. 
64. Everts PA, Devilee RJ, Brown Mahoney C, et al. Platelet gel and ﬁ brin sealant 
reduce allogeneic blood transfusions in total knee arthroplasty. Acta 
Anaesthesiol Scand 2006 May;50(5):593-9. 
65.  Trowbridge CC, Stammers AH, Woods E, et al. Use of platelet gel and its 
effects on infection in cardiac surgery. JECT 2005; 37:381-386. 
66.  Margolis DJ, Kantor J, Santanna J, et al. Effectiveness of platelet releasate for 
the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001;24:483-
488. 
67.  Senet P, Bon FX, Benbunan M, et al. Randomized trial and local biological 
effect of autologous platelets used as adjuvant therapy for chronic venous leg 
ulcers. J Vasc Surg 2003;38:1342-1348.
 
 
PROFORMA    
I) PATIENT IDENTIFICATION DATA :     
NAME  IP/OPD NO.   
AGE  DOA :   
SEX  DOD:   
OCCUPATION     
ADDRESS     
II) CHIEF COMPLAINTS :     
MEDICAL HISTORY :     
Peripheral Neuropathy : ( )   
Nephropathy ( )   
Retinopathy ( )   
PVD ( )   
CVD ( )   
DIABETIC STATUS :     
TYPE :     
DURATION :     
MEDICATION : Oral Hypoglycemics Insulin 
 ( ) ( )
COMPLICATION   Neuropathy ( )   
Vasculopathy ( )   
 
 
 
ULCER DETAIL : 
 
1. Mode of onset 
 
Traumatic ( )  
Spontaneous  ( ) 
Pressure  ( ) 
Others  ( ) 
2. Duration  
 
3. Progress  
 
WOUND OBSERVATION: 
 
1. Site 
2. Size 
3. Shape 
4. Edge 
5. Margin 
6. Floor 
7. Base 
8. Discharge 
9. Surrounding Skin 
 
10. Contractor     
NERUROLOGICAL EXAMINATION :     
VASCULAR EXAMINATION Left  Right  
Popliteal a. ( ) ( )
Ant . Tibial ( ) ( )
Post Tibial ( ) ( )
Dorsalis Pedis ( ) ( )
ANY FOOT DEFORMITY PRESENT :  
Toe deformity 
 
Bunion 
 
Charcots foot 
 
Foot drop  
IF AMPUTATION HAS BEEN DONE 
 
SPECIFY : Date 
 
: Side  
 
: Level  
 
: Cause for amputation  
 
FOOT WEAR ASSESSMENT : 
 
Does patient wear appropriate shoes 
 
Does patient require contact cast immobilization. 
 
INVESTIGATIONS.   
CBC   
FBS   1st _________________ Date :________ Time :_________ 
2nd (24 hr apart ) ___________ Date :________ Time : _________  
Sr. Creatinine 
 
UKB 
 
Urine : Routine 
 
Microscopy 
 
X-ray Foot 
 
AP View 
 
Lat. View 
 
Wound C/s 
 
WOUND AREA MEASUREMENT ON D1 in cm
2 
 
Type of Dressing – saline  dressing ( )
- rh-PDGF  dressing ( )
CONSENT FORM  
FOR OPERATION/ANAESTHESIA/PROCEDURE   
 
I ___________________ Hosp. No.____________ in my full senses  
hereby give my complete consent for ________________ or any other procedure  
       deemed fit which is a / and diagnostic procedure /  transfusion / operation to be  
performed on me / my son / my daughter / my ward __________ age __________  
under any anesthesia deemed fit.  The nature and risks involved in the procedure 
       have been explained to me to my satisfaction. For academic and scientific                      
       purpose operation/procedure may be televised or photographed.    
 
 
 Date:  
Signature/Thumb Impression  
Of Patient/Guardian   
 
 
 Name:  
 Designation:     
 Guardian: 
 
 
 
 
 
 
 
 
 
 
 
                                                     CONSENT 
 
 
I am ready to participate in the study on “A COMPARATIVE STUDY OF 
PLATELET RICH PLASMA VERSUS NORMAL SALINE 
DRESSINGIN DIABETIC FOOT” conducted by Dr.sakthivel.v, post graduate 
student, Department of General Surgery, Government Stanley Medical college, 
chennai. I am ready to undergo  investigations like, blood tests, urine test, 
radiological imaging etc. to confirm the diagnosis of my condition. 
 
I understand that as a part of this study, I will not be subjected to any other treatment 
modalities. 
 
I am assured that being a part of this study, there will not be any financial burden on 
me.  
I know the fact that I can withdraw from the study at any time without showing 
reason and if at all I quit, there will not be any deprivation in the treatment I receive 
in the hospital.  
Hereby, I willingly give consent to take part in this study. 
 
 
                                                                                              Name of the patient 
Date: 
Place:                                                                                             Signature 
 
 
                                                                                                Patients relative 
 
 
MASTER CHART-STUDY GROUP 
Sl.  Age 
  Anti  
X 
 Initial Final 
IA-FA= %Area  Ip.no 0nset Site DM FBS c/s Area in Area in Reduct-  
no & sex ray CA 
 
   Rx   mm2 mm2 ion 
 
             
 
1 
817023 56/m S D I 132 N NOGC 37.52 23.94 13.58 36.2    
2 
5705759 51/f S P I 98 N NOGC 38.88 25.12 13.76 35.4   
 
3 
605162 48/f T D O 123 N NOGC 36.58 23.27 13.31 36.4   
 
4 
605267 52/m S P I 101 N NOGC 47.56 29.30 18.26 38.4    
5 
670355 46/m T D O 76 N NOGC 45.88 32.95 12.93 28.2    
6 
324971 32/m T P I 122 N NOGC 41.60 27.71 13.89 33.4   
 
7 
638973 62/m S D I 99 N PM 45.56 30.80 14.86 32.4    
8 699474 58/m T P I 145 N NOGC 45.36 28.49 16.87 37.2 
 
             
 
9 
693325 54/f T D O 111 N NOGC 58.22 37.50 20.72 35.6    
10 
698534 48/f S P I 100 N NOGC 44.08 27.69 16.39 37.2   
 
11 
715816 64/f S D I 150 N PA 53.76 33.82 19.94 37.1    
12 
698134 36/m T P I 97 N NOGC 69.66 45.14 24.52 35.2    
13 
714977 52/m T P I 90 N NOGC 60.48 40.41 20.07 33.2    
14 
723449 57/m T D I 88 N NOGC 36.40 25.70 10.70 29.4   
 
15 
728805 63/f T P I 98 N NOGC 49.92 36.65 14.27 28.6   
 
16 
728796 65/f S P O 133 N EC 47.12 35.63 11.59 24.6    
17 
743353 45/m T P I 140 N NOGC 71.34 43.24 28.10 39.4    
18 767126 51/m T D O 88 N NOGC 70.98 46.35 24.63 34.7    
19 
761547 38/m T P I 129 N NOGC 57.12 35.31 21.81 38.2   
 
20 
761125 61/f S D I 133 N NOGC 49.92 33.55 16.37 32.8    
21 
808391 52/m T P I 93 N NOGC 49.60 31.15 18.45 37.2    
22 
817023 54/f T P I 133 N PM 67.50 44.69 22.81 33.8    
23 
334017 35/m S D O 79 N NOGC 36.72 24.83 11.89 32.4   
 
24 
410663 64/f S P I 148 N NOGC 51.48 32.75 18.83 36.4    
25 
420071 58/m T P I 111 N NOGC 60.48 37.99 22.49 37.2   
 
MASTER CHART-CONTROL GROUP 
Sl  Age/   Anti-  X-  Initial Final IA - FA % Area  I P No. Onset Site DM FBS C/s Area Area Reduct-  
No. Sex Ray = CA 
 
   Rx   mm2 mm2 ion 
 
             
 
1 832322 63/F S D I 146 N NOGC 46.08 40.46 5.62 12.2 
 
             
 
2 847632 36/M T P O 110 N NOGC 36.54 31.65 4.89 13.4 
 
             
 
3 865342 42/M S P I 122 N NOGC 43.20 35.99 7.21 16.7 
 
             
 
4 432627 51/F T P O 123 N NOGC 53.36 46.32 7.04 13.2 
 
             
 
5 324971 44/F T P I 146 N PA 43.68 37.05 6.63 15.2 
 
             
 
6 259249 56/M S D I 134 N NOGC 47.12 40.43 6.69 14.2 
 
             
 
7 538527 64/M T P I 145 N NOGC 38.86 34.90 3.96 10.2 
 
             
 
8 560571 58/M T D I 186 N NOGC 64.08 55.82 8.26 12.9 
 
             
 
9 582902 54/F T P O 127 N NOGC 34.17 29.66 4.51 13.2 
 
             
 
10 587733 47/M S P I 144 N PM 49.14 43.20 5.94 12.1 
 
             
 
11 633920 53/M T D I 122 N NOGC 52.70 44.22 8.48 16.1 
 
             
 
12 644488 56/F T P I 134 N NOGC 54.28 48.48 5.80 10.7 
 
             
 
13 119208 62/M T P O 139 N NOGC 48.36 42.27 6.09 12.6 
 
             
 
14 644793 46/F S D I 98 N NOGC 64.08 55.63 8.45 13.2 
 
             
 
15 668431 35/M T P I 190 N NOGC 36.72 30.78 5.94 16.2 
 
             
 
16 597042 51/M T P I 95 N EC 57.40 50.69 6.71 11.7 
 
             
 
17 714118 57/F T P I 128 N NOGC 38.94 34.35 4.89 11.8 
 
             
 
18 746552 65/M S D I 144 N NOGC 69.92 59.02 10.90 15.6 
 
             
 
19 515444 55/M T P O 122 N NOGC 48.72 41.76 6.96 14.3 
 
             
 
20 768535 54/M T P I 111 N NOGC 36.72 30.34 6.38 17.4 
 
             
 
21 824053 61/F S D I 140 N PA 42.24 34.44 4.88 10.8 
 
             
 
22 674944 52/F T D I 119 N NOGC 40.12 33.26 6.86 17.1 
 
             
 
23 832323 45/M T P I 146 N NOGC 56.16 39.26 6.90 12.3 
 
             
 
24 535230 64/M S P I 151 N NOGC 48.38 41.52 6.86 14.2 
 
             
 
25 668640 56/F T D I 128 N NOGC 49.68 44.32 5.36 10.8 
 
             
 
 
  KEY FOR USING THE MASTER SHEET 
Sl. No. : Serial number 
M : Male 
F : Female 
IP No : Inpatient Number 
DM : Diabetes mellitus 
FBS : Fasting Blood Sugar 
C/s : Culture sensitivity report 
mm2 : millimetre square 
N : Normal 
T : Traumatic 
S : Spontaneous 
D : Dorsal 
P : Plantar 
I : Insulin 
O : Oral Hypoglycaemic Agents 
NOGC : No Organisms Grown in Culture 
SA : Staphylococcus Aureus 
KP : Klebsiella Pneumonia 
PM : Proteus Mirabilis 
PA : Pseudomonas Aeruginosa 
EC : Eischericia Coli 
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